表达新城疫病毒F蛋白的重组传染性喉气管炎病毒可保护鸡抵抗两种病毒攻击
本研究从SPF鸡分离一株自然无致病力ILTV,构建US9缺失突变株并插入基因VII型NDV的F基因,获得重组株ILTV-ΔUS9-F。单次接种10^4 PFU可对基因VII和IX型NDV提供与La Sota疫苗相似的临床保护,并更有效限制基因VII型NDV复制与排毒。
要点
- ILTV-ΔUS9-F单次10^4 PFU接种对基因VII和IX型NDV提供良好临床保护。
- 该重组株限制基因VII型NDV口咽排毒优于商业La Sota活疫苗。
- 低至10^2和10^3 PFU接种亦提供足够临床保护。
核心结论
- ILTV-ΔUS9-F可能是同时针对ILTV和NDV的双价疫苗候选株。
研究设计与样本
- 基于SPF鸡中自然无致病力ILTV分离株,构建US9缺失突变株并插入基因VII型NDV F基因,获得重组株ILTV-ΔUS9-F。
- 用间接免疫荧光和western blotting确认F蛋白表达,并评估其生长动力学、免疫原性及对NDV攻击的保护效果。
主要发现
- ILTV-ΔUS9-F感染的细胞中F蛋白表达经间接免疫荧光和western blotting确认,插入的F基因稳定表达。
- ILTV-ΔUS9-F生长动力学与野生型ILTV株相当。
- SPF鸡接种ILTV-ΔUS9-F无临床症状,但诱导低水平NDV特异性ELISA和中和抗体。
- 单次10^4 PFU接种对基因VII和IX型NDV的临床保护与商业La Sota活疫苗相似。
- ILTV-ΔUS9-F比La Sota疫苗更有效限制基因VII型NDV在口咽拭子中的复制和排毒,低剂量10^3和10^2 PFU也提供足够临床保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we isolated and identified an infectious laryngotracheitis virus (ILTV) that was naturally avirulent in specific pathogen-free (SPF) chickens, with the aim of developing a more efficacious vaccine against ILTV and Newcastle disease virus (NDV). We constructed a US9-deleted ILTV mutant based on this avirulent ILTV, and then constructed a recombinant ILTV (designated ILTV-ΔUS9-F) expressing the fusion protein (F) of the genotype VII NDV based on the US9-deleted ILTV mutant. Expression of the F protein in ILTV-ΔUS9-F-infected cells was confirmed by indirect immunofluorescence assay and western blotting. The inserted F gene was stably expressed in ILTV-ΔUS9-F. The growth kinetics of ILTV-ΔUS9-F were comparable to those of the wild-type ILTV strain. Vaccination of SPF chickens with ILTV-ΔUS9-F produced no clinical signs but did induce low levels of NDV-specific enzyme-linked immunosorbent assay and neutralizing antibodies. A single vaccination with 104 plaque-forming units (PFU) of ILTV-ΔUS9-F provided good protection against both genotype VII and IX NDVs based on clinical signs, similar to the protection provided by the commercial live La Sota vaccine. Notably, ILTV-ΔUS9-F limited the replication and shedding of genotype VII NDV from oropharyngeal swabs more efficiently than the La Sota vaccine. In addition, vaccination with lower doses (103 and 102 PFU) of ILTV-ΔUS9-F also provided sufficient clinical protection. These results indicated that ILTV-ΔUS9-F may be a bivalent vaccine candidate against both ILTV and NDV.
引用
- Shao Y, Sun J, Han Z, et al. Recombinant infectious laryngotracheitis virus expressing Newcastle disease virus F protein protects chickens against infectious laryngotracheitis virus and Newcastle disease virus challenge. Vaccine. 2018. PMID: 30448332. doi:10.1016/j.vaccine.2018.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。